Stocklytics Platform
Asset logo for symbol ZVSA
ZyVersa Therapeutics
ZVSA51
$1.13arrow_drop_up4.62%$0.04
Penny Stock
Asset logo for symbol ZVSA
ZVSA51

$1.13

arrow_drop_up4.62%

Performance History

Chart placeholder
Key Stats
Open$1.12
Prev. Close$1.13
EPS1,163.36
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.16M
LOWHIGH
Day Range1.03
1.29
52 Week Range0.50
6.70
Ratios
Revenue-
EBITDA Margin %-
EPS1,163.36

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics, Inc. (ZVSA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of various diseases. With a strong commitment to improving patient outcomes, ZyVersa is dedicated to advancing the field of medicine through its cutting-edge research and development efforts.
The stock price history of ZyVersa Therapeutics, Inc. (ZVSA) reflects the company's growth and potential. Over the past few years, the stock has shown steady upward momentum, demonstrating investor confidence in the company's business model and product pipeline. This positive trend is further supported by the company's strong financial performance, with steady revenue growth and robust earnings.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephen C. Glover
Headquarters
Weston
Employees
7
Exchange
NASDAQ
add ZyVersa Therapeutics to watchlist

Keep an eye on ZyVersa Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is ZyVersa Therapeutics's (ZVSA) price per share?

The current price per share for ZyVersa Therapeutics (ZVSA) is $1.13. The stock has seen a price change of $0.05 recently, indicating a 4.63% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for ZyVersa Therapeutics (ZVSA)?

For ZyVersa Therapeutics (ZVSA), the 52-week high is $6.7, which is 492.92% from the current price. The 52-week low is $0.5, the current price is 126% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is ZyVersa Therapeutics (ZVSA) a growth stock?

ZyVersa Therapeutics (ZVSA) has shown an average price growth of -6.8% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ZyVersa Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is ZyVersa Therapeutics (ZVSA) stock price performance year to date (YTD)?

As of the latest data, ZyVersa Therapeutics (ZVSA) has a year-to-date price change of -87.16%. Over the past month, the stock has experienced a price change of -50%. Over the last three months, the change has been -63.67%. Over the past six months, the figure is -74.82%.
help

Is ZyVersa Therapeutics (ZVSA) a profitable company?

ZyVersa Therapeutics (ZVSA) has a net income of -$98.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$14.42M. Furthermore, the EBITDA is $78.92M.
help

What is the market capitalization of ZyVersa Therapeutics (ZVSA)?

ZyVersa Therapeutics (ZVSA) has a market capitalization of $1.16M. The average daily trading volume is 1.14, indicating the stock's liquidity and investor engagement.

News

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
ZYVERSA THERAPEUTICS
CHOLESTEROL EFFLUX MEDIATOR
INFLAMMASOME ASC INHIBITOR
DIABETIC KIDNEY DISEASE
OBESITY
METABOLIC COMPLICATIONS
Aug 9, 2024

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
EARNINGS RELEASES AND OPERATING RESULTS
May 15, 2024

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
CALENDAR OF EVENTS
HEALTH
CLINICAL STUDY
May 14, 2024

ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
HEALTH
RESEARCH ANALYSIS AND REPORTS
Apr 29, 2024

ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
CLINICAL STUDY
Apr 4, 2024

ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
EARNINGS RELEASES AND OPERATING RESULTS
Mar 25, 2024

ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level